The aim of this study was to investigate the activity of BEZ235, a dual phosphatidylinositol-3-kinase (PI3K) and mTOR inhibitor with enhanced activity compared with rapalogs, in preclinical models of MPN, alone and in combination with the JAK2 inhibitor ruxolitinib. Here, JAK2 is linked to myeloproliferative neoplasm.